The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...
CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
Vyvgart Hytrulo is FDA-approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It is given once a week as a shot under the skin. Vyvgart Hytrulo may also be ...
Keyword search terms used were; "chronic inflammatory demyelinating polyneuropathy" or "CIDP" or "chronic inflammatory polyneuropathy" or "autoimmune neuropathies" combined with "drug therapy" or ...
Senators introduce the PLASMA Act to ensure access to affordable plasma-based medicines for rare disease patients.
Citizens JMP raised the firm’s price target on Argenx (ARGX) to $701 from $696 and keeps an Outperform rating on the shares. Argenx’s Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback